Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW Extension: Ranibizumab in ROP
NCT02640664Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Apr 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by Novartis. Started Jun 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02640664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640664.